- Up over 300% year-to-date, PacBio shares have soared on renewed investor enthusiasm and confidence that PacBio's long-read genetic sequencing technology is finally ready to deliver on its potential.
- Third-quarter sales came up short on weaker instrument placements driven by pandemic-related issues, but consumables pull-through was quite good.
- Management will be investing heavily to expand the sales force and continuing to invest in R&D projects aimed at improving the performance, value, and overall utility of PacBio's core technology.
- PacBio now trades at robust multiples, but the $4.2B market cap isn't ridiculous compared to the long-term market opportunity for long-read sequencing technology.
For further details see:
Pacific Biosciences Flying High On HiFi Enthusiasm